How To Understand And Understand The Business Of Advanced Marker Discovery

Transcription

1

2 Advanced Marker Discovery S. L. Executive Summary CONFIDENTIAL The document is an introduction to Advanced Marker Discovery, S.L., ( Amadix or the Company ) and is not an offer to sell, or a solicitation to buy an equity position in Amadix. The information, data, drawings and the like contained in this document are proprietary to Amadix and strictly secret and confidential, and are supplied with the understanding that they will be held secret and confidential. The disclosure by Amadix of information contained herein does not constitute any license or authorization to use or disclose information, ideas or concepts presented. No part of this document may be disclosed to any third party, copied, reproduced or stored on any type of media or used in any way by any party without the express prior, written consent of Amadix or its direct representatives. This document and all related materials must be returned to Amadix upon the Company s request. Confidencial Página 1 de 4

3 EXECUTIVE SUMMARY Industry: Biotechnology, Diagnostics. Management: Rocío Arroyo, PharmD, MBA, CEO Lucia Reinoso, LLB, BA, MBA, CFO Ana Carmen Martin, PhD, Scientific Director Miguel Angel Martinez, M Sc, Intellectual Property Manager Number of FTEs: 8 Current Shareholders: Cross Road Biotech SGECR, S.A. Inveready Seed Capital SCR,S.A. Clave Mayor, SGECR, S.A. ADE Capital Sodical SCR, S.A. Transbiomed S.A. Use of Funds: The Company is poised to move to a more aggressive development phase. To that end the company has just raised up to two million euros ( 2M), which together with available soft funds will support its activities until profitability. Confidencial Página 2 de 4

4 Business Description: Advanced Marker Discovery, S.L. ( Amadix or the Company ) is a development company for innovative diagnostic tools in oncology, either to support the physician s decisions about the right treatment for patients, or anticipating the diagnosis of different types of cancer through a non-invasive test. The Company identifies, evaluates and in-licenses breakthrough discoveries in cancer diagnosis and develops them into marketable products. This is done by leveraging resources through collaborations, resulting in an efficient and flexible process. First Marker: Amadix s leading marker is Choline Kinase Alpha (ChoKα), an enzyme regulating the production of phosphatidylcholine (a key building block in the formation of the cell s membrane). ChoKα is a treatment target of unique quality. ChoKα overexpression is an indicator of the more aggressive nature of the tumor and has been associated with worse clinical prognosis and metastasis in many types of cancers including lung, breast and bladder tumors. First Product: The most advanced product developed by Amadix is a ChoKα gene expressionbased prognostic test that serves as a powerful tool for identifying early stage NSCLC patients in high risk of recurrence, following surgical removal of their cancerous tumor. Thus, ChoKα expression level enables physicians to administer adjuvant treatment to patients in higher risk while avoiding the additional costs and patient suffering associated with under-treating them or over-treating patients in low risk. Over 148,000 stage I NSCLC patients in North America, Europe and Japan can benefit from the test. Confidencial Página 3 de 4

5 Pipeline: Amadix has a pipeline of five innovative tests for diagnostic, prognostic and predictive uses in lung, colon and prostate cancer. The Company is actively looking for innovative projects in cancer diagnosis with a clear commercial rationale, coming from universities, hospitals and research institutions, to broaden the current pipeline through in-licensing of cutting edge technology. Amadix is currently positioning itself as a Spain s Partner of Choice for Oncology diagnostic and development opportunities. A View to 2015: By the end of 2015 Amadix would be in a position to Out- License three diagnostic assays (ChoKα-based test in lung cancer, KIAA-based test in colon cancer and a panel diagnostic test in prostate cancer). According to Amadix s current strategy, a total of 7 New Opportunities are anticipated to be In-Licensed, and undergo biomarker validation until the end of The Opportunity: The Technology Transfer agreement between Amadix and Vall d Hebron Hospital provides the Company with markers that are ready for development. ChoKα, the leading marker, offers commercialization opportunities with a relatively short time to market addressing a clear and significant unmet need of both physicians and patients. In-licensing of new discoveries offer shareholders further untapped potential. Confidencial Página 4 de 4